Table 1. Association between Ubc9 expression and clinicopathologic features of breast cancer.
| Leading malignant neoplasms (ICD code) | Malea | Femalea | Ratio (male: female) |
| Tracheal, bronchial, and lung cancer (ICD 162) | 145.32 | 94.49 | 1.54 |
| Liver and intrahepatic bile duct cancer (ICD 155) | 241.78 | 122.88 | 1.97 |
| Colon and rectal cancer (ICD 153, 154) | 260.49 | 212.00 | 1.23 |
| Stomach cancer (ICD 151) | 77.96 | 49.68 | 1.57 |
| Oral cavity cancer (ICD 140, 141, 143–146, 148, 149) | 169.83 | 23.24 | 7.31 |
| Esophageal cancer (ICD 150) | 35.42 | 5.35 | 6.62 |
| Pancreatic cancer (ICD 157) | 21.08 | 18.02 | 1.17 |
| Non-Hodgkin's lymphoma (ICD 200, 202, 203) | 56.31 | 45.31 | 1.24 |
| Leukemia (ICD 204–208) | 36.85 | 31.09 | 1.19 |
Data were collected between 2005 and 2009.a indicates age-adjusted prevalence rates per 100 000 people.